## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.0% in mid entry zone (3.0-6.0%), top quartile (83rd pct) cross-sectional ranking. Short-term MRS_5 (3.1%) confirms momentum alignment. Strong momentum (+3.9% 5-day acceleration). Outperforming sector by 3.4%. Caution: overbought RSI (74).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($597.84)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference**
- Source: PharmiWeb.com | 20260106T161456 | Neutral | Relevance: 100%
- Thermo Fisher Scientific Inc. announced that its chairman, president, and chief executive officer, Marc N. Casper, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET). A live webcast of the presentation will be available for investors. The company, a world leader in serving science with over $40 billion in annual revenue, aims to enable its customers to make the world healthier, cleaner, and safer.

**2. Here's How Much You'd Have If You Invested $1000 in Thermo Fisher Scientific a Decade Ago**
- Source: www.sharewise.com | 20260106T154332 | Bullish | Relevance: 100%
- An investment of $1,000 in Thermo Fisher Scientific (TMO) ten years ago would now be worth $4,412.68, representing a 341.27% gain, outperforming the S&P 500 and gold over the same period. The company continues to strengthen its growth strategy through innovations and strategic acquisitions, although a highly leveraged balance sheet and currency woes pose some concerns. Analysts anticipate further upside for TMO, with the company embedding OpenAI capabilities and forecasting 5.1% CAGR growth in revenues through 2025-2027.

**3. Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes**
- Source: PharmiWeb.com | 20260106T153432 | Bullish | Relevance: 100%
- Thermo Fisher Scientific has launched the PPD™ CorEvitas™ Obesity Registry to gather real-world evidence on the long-term effectiveness, safety, and patient experience of obesity management therapies. This observational registry will collect insights from clinicians and patients to understand treatment patterns, adherence, satisfaction, and clinical outcomes across diverse care settings. The initiative aims to inform clinical practice, guide future research, and support evidence-based strategies for obesity management, building on CorEvitas Clinical Registries' established model.

**4. Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference**
- Source: BioSpace | 20260106T142436 | Neutral | Relevance: 100%
- Thermo Fisher Scientific Inc. announced that its chairman, president, and chief executive officer, Marc N. Casper, will present at the J.P. Morgan 2026 Healthcare Conference. The presentation is scheduled for Tuesday, January 13, 2026, at 11:15 a.m. (ET), with a live webcast and replay available on the company's investor relations website. Thermo Fisher Scientific is a global leader in serving science with over $40 billion in annual revenue.

**5. Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes**
- Source: BioSpace | 20260106T135833 | Bullish | Relevance: 100%
- Thermo Fisher Scientific has launched the PPD™ CorEvitas™ Obesity Registry to gather real-world evidence on the long-term effectiveness, safety, and patient experience of obesity management therapies. This initiative will collect insights directly from clinicians and patients across diverse care settings to inform treatment patterns, adherence, satisfaction, and clinical outcomes. The registry aims to advance obesity care by providing critical data to the healthcare community, guide future research, and support evidence-based strategies for obesity management.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +3.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 25.2x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +10%, $685 target (+10%)). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $233.2B |
| Beta | 0.91 |
| 52W Range | $385.46 - $628.08 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 25.2 |
| Current P/E | 27.3 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.1% to 5.0% (+3.9% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 3.1% confirms short-term momentum alignment. Outperforming sector by 3.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (4.23), confirming momentum. RSI overbought at 74, risk of mean reversion. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.04% (CS: 84) | Strong |
| RSI_14 | 74.0 | Overbought |
| MACD Histogram | 4.23 | Bullish |
| vs SMA20 | 1.072x | Above |
| vs SMA50 | 1.077x | Above |
| vs SMA200 | 1.277x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $621.06
- **Stop Loss:** $597.84 (3.7% risk)
- **Target:** $655.89 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $34,779.36
- **Portfolio %:** 34.78%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*